On February 19, Johnson & Johnson stock reached a 52-week high of $246.96. I continue to believe that its three key drugs remain Spravato, Darzalex/Darzalex Faspro, and Tremfya, whose total sales grew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results